Following the same approach, one small study used mass cytometry on serially collected samples from 9 AML patients treated with HMA and avelumab, a PD-L1 inhibitor; the ratio of CD4/CD8 and composition of residual T cells emerged as the most important predictors of response to treatment, and AML cells expressed a variety of other immune checkpoints (such as PD-L2, OX40, TIM3) that might be considered for future combination therapy (134). This evidence concerns the gene CD8A and acute myeloid leukemia.